For Pfizer, Bigger as One May Be Better Than Smaller With Two

For Pfizer, Bigger as One May Be Better Than Smaller With Two


By deciding not to split in two after a lengthy evaluation, the New York-based drugmaker is keeping greater leverage with the health insurers and pharmacy benefit managers that have gained increasing power since it first considered a breakup years ago. Had it broken up, Pfizer would have turned into one company with older and generic products, and another with newer products.



from Biotech News